Search Medical Condition
Please enter condition
Please choose location
 

Kirishima, Japan Clinical Trials

A listing of Kirishima, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (4) clinical trials

A Dose Response Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Methotrexate

This study is a multicenter, randomized, double-blind, placebo-controlled, parallel-group comparison study in rheumatoid arthritis participants inadequately responding to methotrexate.

Phase

0.0 miles

Learn More »

A Study to Investigate the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of RO7034067 in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants

Multi-center, randomized, double-blind, placebo-controlled, Phase II study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RO7034067 in adult and pediatric participants with Type 2 and Type 3 SMA. The study consists of two parts, an exploratory dose finding part (Part 1) of RO7034067 for 12 weeks and a ...

Phase

7.05 miles

Learn More »

Phase III Study of GSK1278863 in Japanese Non-dialysis and Peritoneal Dialysis Subjects With Renal Anemia

This is a Phase III, open-label, active-controlled, parallel-group, multi-center study to compare the efficacy (verification of noninferiority) and safety of GSK1278863 administered for 52 weeks versus epoetin beta pegol in approximately 270 Japanese non-dialysis (ND) and 50 peritoneal dialysis (PD) subjects with renal anemia. The study will consist of 2 ...

Phase

8.61 miles

Learn More »

Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)

The study will evaluate the efficacy and safety of imipenem+cilastatin/relebactam (IMI/REL, MK-7655A) in Japanese participants with complicated intra-abdominal infection (cIAI) or complicated urinary tract infection (cUTI).

Phase

8.72 miles

Learn More »